PharVision Advisers’s Evertec EVTC Stock Holding History

PharVision Advisers’s Portfolio EVTC Stock Details EVTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-9,083	Closed	-$264K	–	283
2025 Q4	$264K	Buy	+9,083	New	+$270K	0.13%	357

Other funds holding EVTC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PharVision Advisers's EVTC Position: Q1 2026 in Review

PharVision Advisers sold out of Evertec (EVTC) in Q1 2026, closing a stake of 9,083 shares — an estimated $264K sold.

PharVision Advisers first reported a position in EVTC in Q4 2025 and held it in 1 quarter. The position peaked at $264K in Q4 2025. 261 funds tracked by Wall St. Rank hold EVTC as of Q1 2026.

PharVision Advisers reported no remaining Evertec position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 9,083 Evertec shares in Q1 2026, an estimated $264K.
PharVision Advisers first reported a position in Evertec in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Evertec position peaked at $264K in Q4 2025.
261 funds tracked by Wall St. Rank held Evertec as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.